Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-18T12:27:57.944Z Has data issue: false hasContentIssue false
  • English
  • Français

Columbia Atypical Depression

A Subgroup of Depressives with Better Response to MAOI than to Tricyclic Antidepressants or Placebo

Published online by Cambridge University Press:  06 August 2018

Frederic M. Quitkin ,
Jonathan W. Stewart ,
Patrick J. Mcgrath ,
Elaine Tricamo ,
Judith G. Rabkin ,
Katja Ocepek-Welikson ,
Edward Nunes ,
Wilma Harrison  and
Donald F. Klein
Frederic M. Quitkin*
Affiliation:
New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University
Jonathan W. Stewart
Affiliation:
New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University
Patrick J. Mcgrath
Affiliation:
New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University
Elaine Tricamo
Affiliation:
New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University
Judith G. Rabkin
Affiliation:
New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University
Katja Ocepek-Welikson
Affiliation:
New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University
Edward Nunes
Affiliation:
New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University
Wilma Harrison
Affiliation:
Roerig Division, Pfizer Inc., New York
Donald F. Klein
Affiliation:
New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University
*
∗New York State Psychiatric Institute and College of Physicians and Surgeons of Columbia University, Department of Psychiatry, New York, NY, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

We summarise a series of studies using a MAOI to help establish the validity of a subgroup of depressives referred to as atypical depressives. Patients with reactive mood meeting DSM-III criteria for depressive illness who had associated atypical features (which include hyperphagia, hypersomnolence, leaden paralysis, and rejection sensitivity) were randomised to imipramine, phenelzine and placebo. Non-responders were crossed over, and in all there were over 400 patient trials. Phenelzine consistently was found to be superior to imipramine. Only in trials which included patients lacking atypical, vegetative symptoms was imipramine found to equal phenelzine. We conclude that the researcher and the clinician should consider the relevance of the atypical depressive syndrome.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 163 , Issue S21: Prediction in Psychopharmacology , September 1993 , pp. 30 - 34
Copyright
Copyright © 1993 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM-III). Washington, DC: APA.Google Scholar
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM-III-R). Washington, DC: APA.Google Scholar
Bayer, R. & Spitzer, R. (1985) Neurosis, psychodynamics and DSM-III: a history of the controversy. Archives of General Psychiatry, 42, 187–196.Google Scholar
Bieleski, R. J. & Friedel, R. O. (1976) Predictions of tricyclic antidepressant response. Archives of General Psychiatry, 33, 1479–1489.CrossRefGoogle Scholar
Bloch, R. G., Doonief, A. S., Bucberg, A. S., et al (1954) The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis. Annals of Internal Medicine, 40, 881–900.Google Scholar
Crane, G. E. (1957) Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating disease. Psychiatric Research Reports, 8, 142–152.Google Scholar
Dally, P. & Rhode, P. (1961) Comparison of antidepressant drugs in depressive illness. Lancet, i, 18–20.Google Scholar
Davidson, J. R., Miller, R. D., Turnbull, C. D., et al (1982) Atypical depression. Archives of General Psychiatry, 39, 527–534.Google Scholar
Deragotis, L. R., Lipman, R. S. & Covi, M. D. (1973) Symptom checklist-90 (SCL-90), an out-patient rating scale: preliminary report. Psychopharmacology Bulletin, 9, 13–20.Google Scholar
Fischer, R. A. (1970) Statistical Methods for Research Workers (14th edn), pp. 99–101. New York: Hafner Press.Google Scholar
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology, pp. 217–222. Rockville: US Department of Health, Education and Welfare.Google Scholar
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278–296.Google Scholar
Joyce, P. R. & Paykel, E. S. (1989) Predictors of drug response in depression. Archives of General Psychiatry, 46, 89–99.Google Scholar
Klein, D. F. (1964) Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia, 5, 397–408.Google Scholar
Klein, D. F., Gittelman, R., Quitkin, F. M., et al (1980) Diagnosis and Drug Treatment of Psychiatric Disorders: Adults and Children (2nd edn). Baltimore: Williams & Wilkins.Google Scholar
Kline, N. S. (1958) Clinical experience with oproniazid (Marsilid). Journal of Clinical Experimental Psychopathology, 19 (suppl. 1), 72–78.Google Scholar
Liebowitz, M. R., Quitkin, F. M., Stewart, J. W., et al (1988) Antidepressant specificity in atypical depression. Archives of General Psychiatry, 45, 129–137.CrossRefGoogle ScholarPubMed
McGrath, P. J., Stewart, J. W., Harrison, W., et al (1987) Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacology Bulletin, 23, 169–172.Google Scholar
McNair, D. M. & Kahn, R. J. (1981) Imipramine with benzodiazepines for agoraphobia. In Anxiety: New Research and Changing Concepts (eds Klein, D. F. & Rabkin, J. G.). New York: Raven Press.Google Scholar
Paykel, E. S., Rowan, P. R., Parker, R. R., et al (1982) Response to phenelzine and amitriptyline in subtypes of outpatient depression. Archives of General Psychiatry, 39, 1041–1049.CrossRefGoogle ScholarPubMed
Polit, J. & Young, J. (1971) Anxiety state or masked depression: a study based on the action of monoamine oxidase inhibitors. British Journal of Psychiatry, 119, 143–149.CrossRefGoogle Scholar
Quitkin, F. M., Rifkin, A. & Klein, D. F. (1979) Monoamine oxidase inhibitors: a review of antidepressant effectiveness. Archives of General Psychiatry, 36, 749–760.Google Scholar
Quitkin, F. M., Stewart, J. S., McGrath, P. J., et al (1988) Phenelzine versus imipramine in the treatment of probable atypical depression; defining syndrome boundaries of selective MAOI responders. American Journal of Psychiatry, 145, 306–311.Google Scholar
Quitkin, F. M., McGrath, P. J., Stewart, J. W., et al (1989) Phenelzine and imipramine in mood reactive depressives: further delineation of the syndrome of atypical depression. Archives of General Psychiatry, 46, 787–793.Google Scholar
Quitkin, F. M., McGrath, P. J., Stewart, J. W., et al (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Archives of General Psychiatry, 47, 935–941.Google Scholar
Quitkin, F. M., Harrison, W., Stewart, J. W., et al (1991) Response to phenelzine and imipramine in placebo non-responders with atypical depression: a new application of the crossover design. Archives of General Psychiatry, 48, 319–323.Google Scholar
Ravaris, C. L., Robinson, D. S., Ivest, J. O., et al (1980) Phenelzine and amitriptyline in the treatment of depression: a comparison of present and past studies. Archives of General Psychiatry, 37, 1075–1080.Google Scholar
Reimherr, R. W., Wood, D. R., Byerley, B., et al (1984) Characteristics of responders to fluoxetine. Psychopharmacology Bulletin, 20, 70–72.Google Scholar
Robins, E. & Guze, S. B. (1970) Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. American Journal of Psychiatry, 126, 107–111.CrossRefGoogle ScholarPubMed
Rowan, P. R., Paykel, E. S. & Parker, R. R. (1982) Phenelzine and amitriptyline: effects of symptoms of neurotic depression. British Journal of Psychiatry, 140, 475–483.Google Scholar
Sargent, W. (1961) Drugs in the treatment of depression. British Medical Journal, i, 225–227.Google Scholar
Selikoff, I. J., Robitzek, E. H. & Ornstein, G. G. (1952) Toxicity of hydrazine derivatives of isonicotinic acid in the chemotherapy of human tuberculosis. Quarterly Bulletin Sea View Hospital, 13, 17.Google Scholar
Stewart, J. S., McGrath, P. J., Quitkin, F. M., et al (1989) Relevance of DSM-III depressive subtype and chronicity to antidepressant efficacy in atypical depression: differential response to phenelzine, imipramine and placebo. Archives of General Psychiatry, 46, 1080–1087.Google Scholar
West, E. D. & Dally, P. J. (1959) Effects of iproniazid in depressive syndrome. British Medical Journal, i, 1491–1494.Google Scholar
Young, J. P. R., Lader, M. H. & Hughes, W. C. (1979) Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed out-patients. British Medical Journal Clinical Research, 2, 1315–1317.Google Scholar
Zeller, E. A., Barsky, J., Fouts, J. R., et al (1952) Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl 2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia, 8, 349–350.CrossRefGoogle Scholar
Zitrin, C. M., Klein, D. F. & Woerner, M. G. (1978) Behavior therapy, supportive psychotherapy, imipramine and phobia. Archives of General Psychiatry, 35, 307–315.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.